首页> 外文OA文献 >Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings
【2h】

Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings

机译:在资源限制和大规模人口研究设置中用于临床评估HIV相关神经病和神经性疼痛的仪器的开发,验证和现场测试

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

HIV-associated sensory peripheral neuropathy (HIV-SN) afflicts approximately 50% of patients on antiretroviral therapy, and is associated with significant neuropathic pain. Simple accurate diagnostic instruments are required for clinical research and daily practice in both high- and low-resource setting. A 4-item clinical tool (CHANT: Clinical HIV-associated Neuropathy Tool) assessing symptoms (pain and numbness) and signs (ankle reflexes and vibration sense) was developed by selecting and combining the most accurate measurands from a deep phenotyping study of HIV positive people (Pain In Neuropathy Study–HIV-PINS). CHANT was alpha-tested in silico against the HIV-PINS dataset and then clinically validated and field-tested in HIV-positive cohorts in London, UK and Johannesburg, South Africa. The Utah Early Neuropathy Score (UENS) was used as the reference standard in both settings. In a second step, neuropathic pain in the presence of HIV-SN was assessed using the Douleur Neuropathique en 4 Questions (DN4)-interview and a body map. CHANT achieved high accuracy on alpha-testing with sensitivity and specificity of 82% and 90%, respectively. In 30 patients in London, CHANT diagnosed 43.3% (13/30) HIV-SN (66.7% with neuropathic pain); sensitivity = 100%, specificity = 85%, and likelihood ratio = 6.7 versus UENS, internal consistency = 0.88 (Cronbach alpha), average item-total correlation = 0.73 (Spearman’s Rho), and inter-tester concordance > 0.93 (Spearman’s Rho). In 50 patients in Johannesburg, CHANT diagnosed 66% (33/50) HIV-SN (78.8% neuropathic pain); sensitivity = 74.4%, specificity = 85.7%, and likelihood ratio = 5.29 versus UENS. A positive CHANT score markedly increased of pre- to post-test clinical certainty of HIV-SN from 43% to 83% in London, and from 66% to 92% in Johannesburg. In conclusion, a combination of four easily and quickly assessed clinical items can be used to accurately diagnose HIV-SN. DN4-interview used in the context of bilateral feet pain can be used to identify those with neuropathic pain.
机译:HIV相关的感觉性周围神经病(HIV-SN)约有50%的患者接受抗逆转录病毒治疗,并伴有明显的神经性疼痛。在资源丰富和资源匮乏的环境中,临床研究和日常实践都需要简单,准确的诊断工具。通过对HIV阳性患者进行深入的表型研究,从中选择并结合最准确的被测物,从而开发出了一种用于评估症状(疼痛和麻木)和体征(脚踝反射和振动感)的4项临床工具(CHANT:临床与HIV相关的神经病工具)。人(神经病疼痛研究-HIV-PINS)。对CHANT进行了针对HIV-PINS数据集的计算机模拟测试,然后在英国伦敦和南非约翰内斯堡的HIV阳性队列中进行了临床验证和现场测试。在这两种情况下,均使用犹他州早期神经病评分(UENS)作为参考标准。第二步,使用Douleur Neuropathique en 4 Questions(DN4)-访谈和人体图评估存在HIV-SN时的神经性疼痛。 CHANT在alpha测试中获得了很高的准确性,灵敏度和特异性分别为82%和90%。在伦敦的30名患者中,CHANT诊断出HIV SN占43.3%(13/30)(神经性疼痛占66.7%);敏感性= 100%,特异性= 85%,与UENS的似然比= 6.7,内部一致性= 0.88(Cronbach alpha),平均项目与总相关度= 0.73(Spearman's Rho),测试者间一致性> 0.93(Spearman's Rho) 。在约翰内斯堡的50位患者中,CHANT诊断出66%(33/50)HIV-SN(78.8%神经性疼痛);灵敏度= 74.4%,特异性= 85.7%,似然比= 5.29。在伦敦,测试前和测试后HIV-SN的临床确定性的阳性CHANT评分从43%显着提高,在约翰内斯堡从66%增至92%。总之,可以结合使用四个易于快速评估的临床项目来准确诊断HIV-SN。在双侧脚痛的情况下使用的DN4访谈可用于识别患有神经性疼痛的人。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号